These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12434762)

  • 21. Phase II begins for T-20.
    AIDS Patient Care STDS; 1999 Sep; 13(9):567-8. PubMed ID: 10813040
    [No Abstract]   [Full Text] [Related]  

  • 22. Formal approval for Fuzeon.
    AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
    [No Abstract]   [Full Text] [Related]  

  • 23. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
    AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
    [No Abstract]   [Full Text] [Related]  

  • 25. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 26. Fuzeon combination highly effective.
    AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17219619
    [No Abstract]   [Full Text] [Related]  

  • 27. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 28. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 29. Enfuvirtide access, administration, and patient education.
    Celano SA
    Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
    [No Abstract]   [Full Text] [Related]  

  • 30. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 31. T-20 phase III studies underway.
    Giles C
    Surviv News (Atlanta Ga); 2001 Oct; ():1, 12. PubMed ID: 11708190
    [No Abstract]   [Full Text] [Related]  

  • 32. T-20 and adefovir for salvage therapy -- expect no miracles.
    Gilden D
    GMHC Treat Issues; 1998 Apr; 12(4):6-7. PubMed ID: 11365400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New package inserts for efavirenz and T-20.
    AIDS Clin Care; 2007 Mar; 19(3):24. PubMed ID: 17595717
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 36. Fusion inhibitors: T-20 and T-1249.
    TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
    [No Abstract]   [Full Text] [Related]  

  • 37. [HIV infections: further options for combination therapy].
    Hildegard K
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract]   [Full Text] [Related]  

  • 38. Nailing down another HIV target.
    Richman DD
    Nat Med; 1998 Nov; 4(11):1232-3. PubMed ID: 9809537
    [No Abstract]   [Full Text] [Related]  

  • 39. Fresh data on new anti-HIV drugs presented in Durban.
    Leibovich M
    Posit Living; 2000 Aug; 9(7):16-7. PubMed ID: 12492026
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-HIV agents. T-20 shows its potency.
    TreatmentUpdate; 2002 Aug; 14(6):5-6. PubMed ID: 12238452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.